No clue of what the difference is between this and regular botox injections. Ask your doctor.
It wouldn't have done me any good to ask my doctor about any botox injections because he did nothing, my OT set up the injections.
http://dgnews.docguide.com/study-shows-sustained-incobotulinumtoxina-efficacy-upper-limb-post-stroke-spasticity-over-48-weeks?
For patients with upper-limb post-stroke spasticity, repeated
incobotulinumtoxinA injections demonstrated sustained efficacy in
reducing muscle tone and spasticity-associated disability, researchers
reported here on June 21 at the 20th International Congress of
Parkinson’s Disease and Movement Disorders (MDS).
Petr Kaňovský, MD, Faculty of Medicine and Dentistry, Palaký
University Olomouc, and University Hospital, Olomouc, Czech Republic,
and colleagues have previously shown the 12-week efficacy and safety of
incobotulinumtoxinA 400 U versus placebo in patients suffering from
upper limb spasticity.
The current study was a 36-week open-label extension period of the main trial.
In the main study, patients were randomised to placebo (n = 107) or
incobotulinumtoxinA 400 U (n = 210). Of these, 296 (placebo, 99;
incobotulinumtoxinA, 97) continued into this extension study, for three
further injections of incobotulinumtoxinA 400 U at 12- to 20-week
intervals.
This extension period was completed by 248 patients (82.9%), with outcome measures determined at 4 weeks after each injection.
Outcomes included Ashworth Scale response (≥1-point improvement from
each injection to 4 weeks post-injection) and Disability Assessment
Scale (DAS) response (≥1-point improvement in a patient-selected
principal target domain [hygiene, dressing, limb position or pain] from
study baseline to 4 weeks post-injection), adverse events (AEs), and
antibody testing.
AS responder rates after each incobotulinumtoxinA treatment were
52.3% to 61.8% for wrist flexors, 49.1% to 60.0% for elbow flexors,
54.5% to 64.5% for finger flexors, 33.9% to 41.2% for thumb flexors, and
37.4% to 44.2% for forearm pronators.
Post-injection DAS responder rates for the principal target domain
were 46.2% in the main study, and 52.2%, 62.1, and 59.4% in the
extension study injection cycles.
During the main trial, treatment-related AEs were reported in 3.8%
and 1.9% of patients receiving incobotulinumtoxinA and placebo,
respectively. During the entire 36-week extension study,
treatment-related AE incidence was 3.0%. No serious treatment-related
AEs and no clinical non-responsiveness due to antibodies occurred in the
main trial or in the extension trial.
“These results are impressive because we have a stable response to
each injection in this extension period, so incobotulinumtoxinA is
effective over the longer period of time, with no serious adverse events
at all.”
Funding for this study was provided by Merz Pharmaceuticals GmbH, Germany.
[Presentation title: A Phase 3, Placebo-Controlled Study With an
Open-Label Extension: Sustained IncobotulinumtoxinA Efficacy in
Upper-Limb Post-Stroke Spasticity Over 48 Weeks. Abstract 956]
No comments:
Post a Comment